Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.56B P/E 7.39 EPS this Y 5.30% Ern Qtrly Grth -19.40%
Income 1B Forward P/E 4.74 EPS next Y 3.40% 50D Avg Chg 6.00%
Sales 6.35B PEG 1.39 EPS past 5Y -15.59% 200D Avg Chg -10.00%
Dividend 5.00% Price/Book N/A EPS next 5Y 3.10% 52W High Chg -34.00%
Recommedations 2.80 Quick Ratio 0.86 Shares Outstanding 257.47M 52W Low Chg 16.00%
Insider Own 0.17% ROA 7.27% Shares Float 256.64M Beta 0.82
Inst Own 79.86% ROE - Shares Shorted/Prior 7.76M/8.69M Price 21.81
Gross Margin 58.59% Profit Margin 15.76% Avg. Volume 2,234,525 Target Price 23.14
Oper. Margin 24.02% Earnings Date Oct 31 Volume 1,771,141 Change 0.37%
About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Organon & Co. News
11/08/24 Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
11/05/24 Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
11/05/24 Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
11/03/24 Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
11/01/24 Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)
10/31/24 Organon Reports Results for the Third Quarter Ended September 30, 2024
10/30/24 US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
10/28/24 Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
10/25/24 Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/09/24 Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10/09/24 Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
10/08/24 Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
09/30/24 Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
09/26/24 Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada
09/25/24 Are Options Traders Betting on a Big Move in Organon (OGN) Stock?
09/18/24 Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
05:20 AM Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
08/20/24 Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
08/15/24 Investors Shouldn't Be Too Comfortable With Organon's (NYSE:OGN) Earnings
08/08/24 Organon Second Quarter 2024 Earnings: EPS: US$0.76 (vs US$0.95 in 2Q 2023)
OGN Chatroom

User Image BiotechJedi1728 Posted - 13 hours ago

$OGN Bottomed? Time to add to position.

User Image MrNotSoNice Posted - 1 day ago

$OGN This is crazy cheap. I have a lot but will add more. 🧐📈💵💊

User Image jbhogan Posted - 1 day ago

$OGN Thought this would perform better of late.

User Image pranab74 Posted - 1 day ago

$OGN not seeing support until $13.50. what do u all see? Buy Glta

User Image Fort_Knox_Investments Posted - 2 days ago

$OGN

User Image UncleStock Posted - 3 days ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image JohnHar Posted - 4 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $OGN $ALKS

User Image MrNotSoNice Posted - 5 days ago

$PFE $OGN $MRK $MRNA $GSK Pharma getting hammered on RFK (what an ass), time to buy.

User Image UncleStock Posted - 1 week ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Nosh Posted - 1 week ago

$OGN Out...slight loss...will look lower.

User Image Following_the_trend Posted - 1 week ago

$OGN on W/L

User Image TradingLive Posted - 1 week ago

$OGN Like to see it close to 19 and build a base for further breakout while collecting dividend.

User Image Alphasearch Posted - 1 week ago

$OGN Added again, 2 more bounces of the 5 DMA and going higher. I am making a bottom call given the support at Feb lows. Holding just under half position

User Image juzbeachy Posted - 1 week ago

@Cloudburn @claybridge I still worry about the dilution. You are almost guaranteed a significant bounce because I sold a portion of my position today. I put it in $FLNG and $OGN and $wba. All beaten down like NFE, but all pay substantial divi.

User Image Alphasearch Posted - 1 week ago

$OGN Back into this name with 1/3 position that I sold earlier this year in the $20. Stock caught support at February lows last week and today popped then fell and caught on 5 DMA which it has been below for weeks. Stock has been under pressure due to an acquisition that management claimed will be dilutive next year. Stock also hit resistance at the highest high Anchored VWAP of from Jan 2022 of $18.99. Buy it today and get a 7% dividend which 1/4 gets later this month.

User Image Stocksrunner Posted - 1 week ago

🚨 Pre-Market Teaser! Big moves brewing this morning for $NXL $OGN $MPWR $CRDO $UPST 👀. Short squeezes? Bullish turnarounds? https://stocksrunner.com/posts/1339

User Image UncleStock Posted - 1 week ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image spray_paint Posted - 2 weeks ago

$OGN Gap from Feb was filled and the bar is outside of the lower band. Expecting a bounce here.

User Image TradingLive Posted - 2 weeks ago

$OGN Started a LT position 2K at 16.10, after selling the free shares from MRK at $38+ back in 2022

User Image profit_guru Posted - 2 weeks ago

$OGN - looks like all pharma stocks will rally tomorrow as there will be less regulations and less taxes if trump wins ..near term 20…imo

User Image Stocksrunner Posted - 2 weeks ago

$OGN: 🔍 Organon shows a relative strength alert. With a solid dividend yield, this one could be a hidden gem among the oversold stocks. https://stocksrunner.com/posts/1327

User Image profit_guru Posted - 2 weeks ago

$OGN - if Harris wins tonight…this will rally above 20 tomorrow…imo

User Image frankster Posted - 2 weeks ago

$OGN is a great entry here; added another 2000 shares. delay will be long forgotten, and its short-term bleep.

User Image CDMO Posted - 2 weeks ago

$OGN somebody knew yesterday...game is rigged Organon [...] today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA ® (tapinarof) cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of December 12, 2024. The FDA has not raised any concerns regarding the safety and efficacy of VTAMA nor have they raised any concerns regarding the approvability of this indication.

User Image MrNotSoNice Posted - 2 weeks ago

$OGN Buying here 😃

User Image Justinian Posted - 2 weeks ago

$OGN added as an initial investment. Want to just get 100 shares of this. Nothing too big yet

User Image Nosh Posted - 2 weeks ago

$OGN Had a small starter now a small/medium sized position.

User Image Following_the_trend Posted - 2 weeks ago

$OGN Bottom fishing (small) in a quality Co.

User Image vsfan Posted - 2 weeks ago

$OGN about 10% down since ER high, what is this price action about?

User Image howardlindzon Posted - 2 weeks ago

love the charts of the day $ASML $SPY $XLK $QQQ $OGN

Analyst Ratings
JP Morgan Underweight Sep 6, 24
Goldman Sachs Neutral May 6, 24
Goldman Sachs Neutral May 3, 24
Piper Sandler Overweight Apr 29, 24
Goldman Sachs Neutral Feb 20, 24
Piper Sandler Overweight Nov 22, 23
Goldman Sachs Neutral Nov 3, 23
Piper Sandler Overweight Oct 25, 23
Morgan Stanley Equal-Weight Oct 11, 23